Biomarker discovery pipeline

TUMOR TYPE CANCER SUBTYPE TYPE OF CLASSIFIER TYPE OF THERAPY MAIN TARGET DISCOVERY PROTOTYPE ASSAY ANALITYCAL VALIDATION CLINICAL VALIDATION REGULATORY APPROVAL
BREAST HR+ HER- prognostic hormonal / chemotherapy

Title

15%
predictive targeted therapy CDK4/6

Title

55%
predictive targeted therapy PIK3CA

Title

40%
predictive targeted therapy ATR

Title

40%
predictive targeted therapy PARP

Title

40%
TNBC prognostic chemotherapy

Title

15%
predictive targeted therapy TROP-2

Title

15%
HER2+ predictive targeted therapy HER2

Title

55%
OVARIAN HGSC predictive targeted therapy PARP

Title

40%
PANCREATIC PDAC prognostic chemotherapy

Title

15%
predictive targeted therapy PARP

Title

15%
LUNG NSCCL predictive immunotherapy PD-1 / PD-L1

Title

15%
predictive targeted therapy EGFR

Title

15%
predictive targeted therapy ALK

Title

15%

TUMOR TYPE: BREAST

CANCER SUBTYPE: HR+ HER-

CLASSIFIER: prognostic
THERAPY: hormonal / chemotherapy

-

15%

CLASSIFIER: predictive
THERAPY: targeted

CDK4/6

55%

CLASSIFIER: predictive
THERAPY: targeted

PIK3CA/mTOR

15%

CLASSIFIER: predictive
THERAPY: targeted

ATRi

40%

CLASSIFIER: predictive
THERAPY: targeted

PARP

40%

CANCER SUBTYPE: TNBC

CLASSIFIER: prognostic
THERAPY: chemotherapy

-

15%

CLASSIFIER: predictive
THERAPY: targeted

TROP-2

15%

CANCER SUBTYPE: HER2+

CLASSIFIER: predictive
THERAPY: targeted

HER2

55%

TUMOR TYPE: OVARIAN

CANCER SUBTYPE: HGSC

CLASSIFIER: predictive
THERAPY: targeted

PARP

40%

TUMOR TYPE: PANCREATIC

CANCER SUBTYPE: PDAC

CLASSIFIER: prognostic
THERAPY: chemotherapy

-

15%

CLASSIFIER: predictive
THERAPY: targeted

PARP

15%

TUMOR TYPE: LUNG

CANCER SUBTYPE: NSCCL

CLASSIFIER: predictive
THERAPY: immunotherapy

PD-1 / DL-L1

15%

CLASSIFIER: predictive
THERAPY: targeted

EFGR

15%

CLASSIFIER: predictive
THERAPY: targeted

ALK

15%

TECHNICAL NOTES

Read our technotes to learn how we constructed the genomic classifiers – from whole-genome data mining, feature extraction and engineering, through AI model development and retrospective validation.

_ALICE

A stratification classifier for CARBOPLATIN/PARP INHIBITION THERAPY that broadens standard HRD diagnostic testing by additional 44 genomic biomarkers.

Download



    I'm a patientI'm a physicianI'm a student
    I have read and agree to privacy policy and terms of service
    privacy policy
    terms of service

    CDK4/6iDx

    The first, multi-biomarker test FOR SELECTING RESPONDERS TO CDK4/6 INHIBITOR THERAPY in HR+/HER2- breast cancer.

    Download



      I'm a patientI'm a physicianI'm a student
      I have read and agree to privacy policy and terms of service
      privacy policy
      terms of service

      Any questions?

      Contact us

      Contact page